Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study

References

• Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 2013;369:754–62.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780–7.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Van AG, Reinisch W, Colombel JF, D’Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257–65.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Panaccione R, Huang B, Pollack PF, Lazar A, et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 2013;19:1700–9.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, D’Haens G, Van AG, Wolf D, Kron M, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013;37:204–13.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 2014;146:110–18.
   PubMed Web of Science ®Google Scholar
• Oussalah A, Laclotte C, Chevaux JB, Bensenane M, Babouri A, Serre AA, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008;28:966–72.
   PubMed Web of Science ®Google Scholar
• Garcia-Bosch O, Gisbert JP, Canas-Ventura A, Merino O, Cabriada JL, Garcia-Sanchez V, et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 2013;7:717–22.
   PubMed Web of Science ®Google Scholar
• McDermott E, Murphy S, Keegan D, O’Donoghue D, Mulcahy H, Doherty G. Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohns Colitis 2013;7:150–3.
   PubMed Web of Science ®Google Scholar
• Barreiro-de AM, Garcia-Bosch O, Gordillo J, Manosa M, Menchen L, Souto R, et al. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. Eur J Gastroenterol Hepatol 2012;24:756–8.
   Google Scholar
• Taxonera C, Estelles J, Fernandez-Blanco I, Merino O, Marin-Jimenez I, Barreiro-de AM, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther 2011;33:340–8.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Biancone L, Daperno M, Coli A, Pugliese D, Annese V, et al. Adalimumab in active ulcerative colitis: a "real-life" observational study. Dig Liver Dis 2013;45:738–43.
   PubMedGoogle Scholar
• Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2014;39:660–71.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohns Colitis 2014;8:571–81.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Peyrin-Biroulet L, Lucenteforte E, Virgili G, Moja L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 2014;160:704–11.
   PubMed Web of Science ®Google Scholar
• Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C. Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD. Inflamm Bowel Dis 2014;20:1714–21.
   PubMed Web of Science ®Google Scholar
• Danish National Guidelines for Biologic Treatment of IBD. Available from http://www.regioner dk/∼/media/Mediebibliotek_2011/SUNDHED/Medicin/Rådet%20for%20Anvendelse%20af%20Dyr%20Sygehusmedicin/211405%20-%20kroniske%20Lægemiddelrekom.ashx.
   Google Scholar
• Teisner AS, Ainsworth MA, Brynskov J. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience. Scand J Gastroenterol 2010;45:1457–63.
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–53.
   PubMed Web of Science ®Google Scholar
• Afif W, Leighton JA, Hanauer SB, Loftus EVJr, Faubion WA, Pardi DS, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009;15:1302–7.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease. Scand J Gastroenterol 2011;46:310–18.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Marin AC, McNicholl AG, Chaparro M. Meta-analysis on the efficacy of a second-line anti-TNF in inflammatory bowel disease patients with failure to a previous anti-TNF treatment. Gastroenterology 2014;146:S–247.
   Google Scholar
• Humira: EPAR - product information. Available from http://www.ema.europa.eu.
   Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Munck LK, Christensen LA, et al. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn’s disease. J Crohns Colitis 2015. [Epub ahead of print].
   Google Scholar
• Roblin X, Rinaudo M, Del TE, Phelip JM, Genin C, Peyrin-Biroulet L, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol 2014;109:1250–6.
   PubMed Web of Science ®Google Scholar